newsfilter
← Latest News
GlobeNewswire·

YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities

  • YD Bio Limited announced that its licensing partner EG Biomed US Inc. received CAP accreditation for its CLIA-certified laboratory in Bothell, Washington.
  • The CAP accreditation confirms EG BioMed meets gold standard quality assurance protocols & strengthens its ability to deliver advanced laboratory-developed tests for YD Bio's cancer detection programs.
  • Dr. Ethan Shen, CEO of YD Bio, stated the recognition underscores the company's commitment to precision diagnostics & improving patient outcomes.
  • YD Bio & EG BioMed plan to expand their diagnostic portfolio focusing on early cancer detection & monitoring alongside ophthalmology products.
  • Ruo-Kai Lin, Chief R&D Officer of EG BioMed, presented new findings on a novel circulating cell-free DNA biomarker for pancreatic cancer at the AACR conference in Boston.
  • The presented biomarker shows potential to monitor metastasis & disease progression in advanced pancreatic cancer.
  • YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection, ophthalmologic innovations, & stem cell therapies.
  • The press release includes standard forward-looking statements warning investors of risks & uncertainties regarding future expectations.